A Phase I/ II Study of Hypofractionated Radiotherapy With Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients Over 70 Years Old With Newly Diagnosed Glioblastoma
Phase of Trial: Phase I/II
Latest Information Update: 23 Jan 2019
Price : $35 *
At a glance
- Drugs Temozolomide (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Adverse reactions
- 14 Jan 2019 Planned End Date changed from 1 May 2019 to 1 May 2025.
- 14 Jan 2019 Planned primary completion date changed from 1 May 2018 to 1 May 2025.
- 29 Sep 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.